Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Group B Streptococcus Vaccine (GBS-NN/NN2 With Alhydrogel) in Healthy Female Subjects Aged 18 to 40

Next Previous
Trial Profile

A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Group B Streptococcus Vaccine (GBS-NN/NN2 With Alhydrogel) in Healthy Female Subjects Aged 18 to 40

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 04 Feb 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GBS NN (Primary) ; Aluminium hydroxide
  • Indications Streptococcal infections
  • Focus Adverse reactions
  • Acronyms MVX0002
  • Sponsors Minervax

Most Recent Events

  • 20 May 2020 Status changed from active, no longer recruiting to completed.
  • 10 Apr 2019 Status changed from recruiting to active, no longer recruiting.
  • 22 Jan 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top